Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phase Ib pancreatic cancer data demonstrate Halozyme hyaluronan thesis

This article was originally published in Scrip

Executive Summary

Progression-free survival (PFS) was twice as high and overall survival was three times as high for pancreatic cancer patients with high levels of tumor-associated hyaluronan (HA) who were treated with Halozyme Therapeutics's PEGPH20 (pegylated recombinant human hyaluronidase) plus gemcitabine than for patients whose tumors had low HA levels in a Phase Ib clinical trial.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC022935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel